Condition (MeSH)
Condylomata Acuminata
ClinicalTrials.gov lists 112 trials for Condylomata Acuminata or a narrower condition beneath it. Merck Sharp & Dohme LLC has the most among industry and government lead sponsors, with 19.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
112 of the 112 trials are tagged with Condylomata Acuminata itself; the rest are tagged with a narrower condition beneath it.
When did Condylomata Acuminata trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2024 | 6 |
| 2023 | 1 |
| 2022 | 10 |
| 2021 | 6 |
| 2020 | 9 |
| 2019 | 7 |
| 2018 | 3 |
| 2017 | 5 |
Showing 10 of 25 earlier years.
No forecast is made for this condition: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 82 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Condylomata Acuminata trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 13 |
| Phase 1/2 | 3 |
| Phase 2 | 19 |
| Phase 2/3 | 3 |
| Phase 3 | 39 |
| Phase 4 | 5 |
| Not applicable | 10 |
| Observational | 20 |
How many Condylomata Acuminata trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 5 |
| Active, not recruiting | 8 |
| Completed | 74 |
| Terminated | 5 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Condylomata Acuminata trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 19 |
| Shanghai Bovax Biotechnology Co., Ltd. | 12 |
| Beijing Health Guard Biotechnology, Inc | 3 |
| MediGene | 3 |
| Gilead Sciences | 2 |
Showing 5 of 9 sponsors.
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| V503 | 4 |
| GARDASIL ®9 | 4 |
| 9vHPV Vaccine | 3 |
| Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) | 3 |
| HPV (Human Papillomavirus) Vaccine | 3 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Condylomata Acuminata trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Abortion induced | 140 | 4 |
| Abortion spontaneous | 76 | 2 |
| Overdose | 40 | 2 |
| Appendicitis | 38 | 7 |
| Cephalo-pelvic disproportion | 19 | 4 |
Showing 5 of 10 adverse events.
Which publications cover Condylomata Acuminata? (99)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Effectiveness of an intervention to increase uptake of voluntary medical male circumcision among men with sexually transmitted infections in Malawi: a preinterventional and postinterventional study. | BMJ open | 2023 | Yes |
| Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. | The Lancet. Infectious diseases | 2022 | Yes |
| Laser therapy in cutaneous and genital warts: A review article. | Dermatologic therapy | 2021 | Yes |
| Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts. | American journal of clinical dermatology | 2021 | Yes |
| 2019 IUSTI-Europe guideline for the management of anogenital warts. | Journal of the European Academy of Dermatology and Venereology : JEADV | 2020 | Yes |
Showing 5 of 99 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.